Implication of sphingosin-1-phosphate in cardiovascular regulation.
Implication of sphingosin-1-phosphate in cardiovascular regulation.
复制标题
DOI：
10.2741/4458
复制
发表时间：
2016-06-01
期刊：
影响因子：
--
通讯作者：
Zhang F
中科院分区：
文献类型：
--
作者：
Li N;Zhang F
鞘氨醇-1-磷酸（S1P）是鞘氨醇激酶催化鞘氨醇磷酸化产生的具有生物活性的鞘脂代谢物。S1P主要通过其高亲和力的g蛋白偶联受体起作用，参与包括心血管系统在内的多个系统的调控。研究表明，S1P信号参与心脏慢变性和渐变性的调节，并有助于心脏保护和心脏重塑；S1P信号调节血管功能，如血管张力和内皮屏障，并具有抗动脉粥样硬化作用；S1P信号也参与血压的调节。因此，操纵S1P信号可能为心血管疾病的治疗提供新的途径。由于一些S1P受体调节剂和鞘氨酸激酶抑制剂已被批准或正在临床试验中用于治疗其他疾病，这可能会加快这些基于S1P的药物在心血管疾病中的测试和实施。
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite generated by phosphorylation of sphingosine catalyzed by sphingosine kinase. S1P acts mainly through its high affinity G-protein-coupled receptors and participates in the regulation of multiple systems, including cardiovascular system. It has been shown that S1P signaling is involved in the regulation of cardiac chronotropy and inotropy and contributes to cardioprotection as well as cardiac remodeling; S1P signaling regulates vascular function, such as vascular tone and endothelial barrier, and possesses an anti-atherosclerotic effect; S1P signaling is also implicated in the regulation of blood pressure. Therefore, manipulation of S1P signaling may offer novel therapeutic approaches to cardiovascular diseases. As several S1P receptor modulators and sphingosine kinase inhibitors have been approved or under clinical trials for the treatment of other diseases, it may expedite the test and implementation of these S1P-based drugs in cardiovascular diseases.